查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1881438

憂鬱症藥物市場－全球產業規模、佔有率、趨勢、機會和預測，依藥物類別、疾病類型、藥物類型、地區和競爭格局分類，2020-2030年預測

Depression Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Disorder Type, By Drug Type, By region, and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球憂鬱症藥物市場規模預計將從2024年的184.6億美元成長至2030年的217.9億美元，年複合成長率為2.8%。全球憂鬱症藥物市場涵蓋專門用於治療重度憂鬱症及相關精神健康問題的藥物，這些藥物主要透過調節大腦中的神經傳導物質活性發揮作用。推動該市場擴張的關鍵因素包括：全球精神健康障礙盛行率不斷上升、大眾對這些疾病的認知度提高導致診斷率增加，以及藥物研發的持續進步不斷推出新的治療方案。

市場概覽
預測期 2026-2030
2024年市場規模 184.6億美元
2030年市場規模 217.9億美元
2025-2030年複合年成長率 2.8%
成長最快的細分市場 品牌藥品
最大的市場 北美洲

主要市場促進因素

主要市場挑戰

主要市場趨勢

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球憂鬱症藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依藥物類別（非典型抗精神病藥物、5-羥色胺-去甲腎上腺素再攝取抑制劑（SNRIs）、選擇性5-羥色胺再攝取抑制劑（SSRIs）、中樞神經系統（CNS）興奮劑、三環類抗憂鬱劑、單胺氧化酶抑制劑、其他）
    • 依疾病類型分類（重度憂鬱症、強迫症、廣泛性焦慮症、恐慌症、其他）
    • 依藥物類型（通用名藥物、品牌藥物）
    • 按地區
    • 按公司（2024 年）
  • 市場地圖

第6章：北美抗憂鬱藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲抗憂鬱藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區抗憂鬱藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲憂鬱症藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲憂鬱症藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章：市場動態

  • 促進要素
  • 挑戰

第12章：市場趨勢與發展

  • 併購（如有）
  • 產品發布（如有）
  • 最新進展

第13章：全球憂鬱症藥物市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商議價能力
  • 顧客的力量
  • 替代產品的威脅

第15章：競爭格局

  • Otsuka Holdings Co., Ltd.
  • Pfizer, Inc.
  • Eli Lilly and Company
  • AstraZeneca plc.
  • Novartis AG
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline plc.
  • Takeda Pharmaceutical Co., Ltd.
  • AbbVie, Inc.
  • Johnson & Johnson

第16章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 21812

The Global Depression Drugs Market will grow from USD 18.46 Billion in 2024 to USD 21.79 Billion by 2030 at a 2.8% CAGR. The global depression drugs market encompasses pharmaceutical agents specifically developed to treat major depressive disorder and related mental health conditions, functioning primarily by modulating neurotransmitter activity in the brain. Key drivers bolstering this market's expansion include the escalating global prevalence of mental health disorders, a growing public awareness of these conditions leading to increased diagnoses, and continuous advancements in pharmaceutical research and development introducing novel therapeutic options.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 18.46 Billion
Market Size 2030USD 21.79 Billion
CAGR 2025-20302.8%
Fastest Growing SegmentBranded Drugs
Largest MarketNorth America

Key Market Drivers

The increasing prevalence of depressive disorders fundamentally propels the global depression drugs market by expanding the patient population requiring pharmacological interventions. These conditions represent a substantial portion of the global disease burden, necessitating a continuous supply of effective treatments. According to the World Health Organization, in September 2025, in their 'World Mental Health Today: Latest Data' and 'Mental Health Atlas 2024' reports, over one billion people worldwide are living with mental health disorders, with anxiety and depressive disorders collectively constituting more than two-thirds of all cases.

Key Market Challenges

A significant challenge impeding the sustained growth of the global depression drugs market is the limited accessibility of mental healthcare services and essential medications, particularly within emerging economies. These regions frequently contend with inadequate healthcare infrastructure and insufficient numbers of mental health professionals. This accessibility gap directly restricts patient reach and the uptake of necessary pharmacological interventions, thereby hindering overall market expansion.

Key Market Trends

The emergence of psychedelic-assisted treatment modalities represents a significant shift in the therapeutic landscape for depression, offering novel mechanisms of action beyond conventional monoaminergic approaches. These therapies, often involving compounds like psilocybin and lysergic acid diethylamide (LSD) alongside psychological support, are demonstrating promising efficacy, particularly for treatment-resistant depression. For instance, Compass Pathways announced in June 2025 that its COMP360 psilocybin achieved the primary endpoint in a Phase 3 trial for treatment-resistant depression, showing a highly statistically significant and clinically meaningful reduction in depressive symptoms after six weeks.

Key Market Players

  • Otsuka Holdings Co., Ltd.
  • Pfizer, Inc.
  • Eli Lilly and Company
  • AstraZeneca plc.
  • Novartis AG
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline plc.
  • Takeda Pharmaceutical Co., Ltd.
  • AbbVie, Inc.
  • Johnson & Johnson

Report Scope:

In this report, the Global Depression Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Depression Drugs Market, By Drug Class:

  • Atypical Antipsychotics
  • Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
  • Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Central Nervous System (CNS) Stimulants
  • Tricyclic Antidepressants
  • Monoamine Oxidase Inhibitors
  • Others

Depression Drugs Market, By Disorder Type:

  • Major Depressive Disorder
  • Obsessive-Compulsive Disorder
  • Generalized Anxiety Disorder
  • Panic Disorder
  • Others

Depression Drugs Market, By Drug Type:

  • Generic Drugs
  • Branded Drugs

Depression Drugs Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Depression Drugs Market.

Available Customizations:

Global Depression Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Depression Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class (Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Selective Serotonin Reuptake Inhibitors (SSRIs), Central Nervous System (CNS) Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors, Others)
    • 5.2.2. By Disorder Type (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, Others)
    • 5.2.3. By Drug Type (Generic Drugs, Branded Drugs)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. North America Depression Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Disorder Type
    • 6.2.3. By Drug Type
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Depression Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Disorder Type
        • 6.3.1.2.3. By Drug Type
    • 6.3.2. Canada Depression Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Disorder Type
        • 6.3.2.2.3. By Drug Type
    • 6.3.3. Mexico Depression Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Disorder Type
        • 6.3.3.2.3. By Drug Type

7. Europe Depression Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Disorder Type
    • 7.2.3. By Drug Type
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Depression Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Disorder Type
        • 7.3.1.2.3. By Drug Type
    • 7.3.2. France Depression Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Disorder Type
        • 7.3.2.2.3. By Drug Type
    • 7.3.3. United Kingdom Depression Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Disorder Type
        • 7.3.3.2.3. By Drug Type
    • 7.3.4. Italy Depression Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Disorder Type
        • 7.3.4.2.3. By Drug Type
    • 7.3.5. Spain Depression Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Disorder Type
        • 7.3.5.2.3. By Drug Type

8. Asia Pacific Depression Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Disorder Type
    • 8.2.3. By Drug Type
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Depression Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Disorder Type
        • 8.3.1.2.3. By Drug Type
    • 8.3.2. India Depression Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Disorder Type
        • 8.3.2.2.3. By Drug Type
    • 8.3.3. Japan Depression Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Disorder Type
        • 8.3.3.2.3. By Drug Type
    • 8.3.4. South Korea Depression Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Disorder Type
        • 8.3.4.2.3. By Drug Type
    • 8.3.5. Australia Depression Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Disorder Type
        • 8.3.5.2.3. By Drug Type

9. Middle East & Africa Depression Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Disorder Type
    • 9.2.3. By Drug Type
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Depression Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Disorder Type
        • 9.3.1.2.3. By Drug Type
    • 9.3.2. UAE Depression Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Disorder Type
        • 9.3.2.2.3. By Drug Type
    • 9.3.3. South Africa Depression Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Disorder Type
        • 9.3.3.2.3. By Drug Type

10. South America Depression Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Disorder Type
    • 10.2.3. By Drug Type
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Depression Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Disorder Type
        • 10.3.1.2.3. By Drug Type
    • 10.3.2. Colombia Depression Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Disorder Type
        • 10.3.2.2.3. By Drug Type
    • 10.3.3. Argentina Depression Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Disorder Type
        • 10.3.3.2.3. By Drug Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Depression Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Otsuka Holdings Co., Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Pfizer, Inc.
  • 15.3. Eli Lilly and Company
  • 15.4. AstraZeneca plc.
  • 15.5. Novartis AG
  • 15.6. Bristol-Myers Squibb Company
  • 15.7. GlaxoSmithKline plc.
  • 15.8. Takeda Pharmaceutical Co., Ltd.
  • 15.9. AbbVie, Inc.
  • 15.10. Johnson & Johnson

16. Strategic Recommendations

17. About Us & Disclaimer